Application of super antigen or modified body thereof in improving intestinal function

Through oral administration of Staphylococcus aureus enterotoxin or its modified version, the intestinal microbial structure and barrier function are regulated, and the gap in intestinal health protection is solved, and the improvement of intestinal health and disease prevention effects are achieved.

CN119054931APending Publication Date: 2024-12-03SHENYANG INST OF APPL ECOLOGY CHINESE ACAD OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410995068.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art has not yet explored the application of Staphylococcus aureus superantigen as an oral preparation in the functions of intestinal microorganisms and intestinal barriers, resulting in gaps in intestinal health protection.

Method used

Staphylococcus aureus enterotoxin or its modification is used as super antigen, and the intestinal microbial structure is regulated through oral administration, short-chain fatty acid production is promoted, intestinal barrier function is enhanced, and intestinal health is improved.

Benefits of technology

Oral superantigen or its modifier can tolerate the body's temperature and gastric acid, regulate the intestinal flora, increase the content of short-chain fatty acids, enhance the function of the intestinal barrier, improve intestinal health, and prevent and treat related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119054931A_ABST
    Figure CN119054931A_ABST
Patent Text Reader

Abstract

The invention discloses application of a super antigen or a modified body thereof in preparation of food or medicine for improving intestinal functions and further protecting intestinal health. The super antigen is selected from staphylococcus aureus enterotoxin. After oral administration of the preparation, intestinal villus growth is promoted, the villus-gland ratio of the small intestine is increased, and the intestinal tissue structure is improved; the intestinal microbial population structure can be regulated, controlled and optimized, beneficial bacteria are enriched, the abundance of harmful bacteria is reduced, and the generation of intestinal short-chain fatty acid is effectively improved; the expression of intestinal mucosa protein and tight junction protein is up-regulated, and the barrier function of intestinal mucosa is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological products, and in particular to the use of a superantigen or a modified form thereof in the preparation of food or medicine for improving intestinal function. Background Art

[0002] The intestine is the largest interface between the human body and the external environment. It is not only an important digestive and absorptive organ, but also plays a key role in defense and barrier functions. The nutrients needed for human activities are mainly absorbed through the intestine, and more than 80% of toxins are excreted through the intestine. At the same time, the intestine plays an important immune function, isolating external harmful substances from invading the body. The normal function of the intestine provides a strong guarantee for the normal operation of the body.

[0003] The intestinal tissue environment is a paradise for microorganisms. The total number of microorganisms living in the intestinal environment is about 10 14 Intestinal microorganisms form an additional barrier in the mucus layer, isolating pathogens, particles and pollutants from the internal environment, thus supplementing the intestinal barrier. A large number of microorganisms can produce a large number of metabolites, which are absorbed by the intestine and act on the human body, playing an important role in the body's immunity, nutrient absorption, information transmission, etc. The short-chain fatty acids produced by intestinal microorganisms in decomposing dietary fiber, such as acetic acid, propionic acid, butyric acid, play an important role in regulating intestinal absorption and microbial flora structure, and can also effectively prevent or alleviate intestinal diseases such as ulcerative colitis, Crohn's disease, and intestinal cancer. Intestinal microorganisms also participate in carbohydrate metabolism, protein metabolism, amino acid metabolism, bile acid metabolism, etc. In addition, there are some intestinal microorganisms that can promote the secretion of mucin in the intestine, such as Lactobacillus and Bifidobacterium. They help the secretion of mucin, thicken the mucus layer on the surface of the intestine, provide a barrier for the surface of the intestine, and prevent the invasion of pathogenic microorganisms. The intestinal barrier function can effectively prevent harmful substances in the intestine from passing through the intestinal epithelial cells and entering the body's circulatory system and other tissues and organs. The participants who maintain the intestinal barrier function mainly include: intestinal epithelial cells, intestinal mucosa, gastric acid, short-chain fatty acids, etc. These participants together constitute the intestinal barrier and perform the intestinal barrier function. Among them, the intestinal mucosal barrier separates the external environment from the internal environment of the body, and as a selectively permeable barrier, it effectively prevents the passage of harmful microorganisms and toxins, while ensuring the flow of water, ions, solutes, and nutrients.

[0004] Through the above studies, we can conclude that intestinal microorganisms and intestinal barrier function play an important role in maintaining intestinal health. Intestinal microbial imbalance and intestinal barrier function disorder can cause the occurrence and development of a series of intestinal diseases, thereby affecting the health of the whole body. Therefore, it is feasible and worthwhile to prevent and treat intestinal diseases by improving intestinal microorganisms and enhancing the intestinal mucosal barrier.

[0005] Superantigens (SAg) include metabolites of Staphylococcus aureus (abbreviated as S. aureus), which are soluble proteins with biological immune activation activity. S. aureus superantigen protein is thermally stable, can still maintain biological activity in 100°C boiling water for 30 minutes, and can not be decomposed in the environment of pancreatic enzymes and pepsin. Superantigen SAg can activate the proliferation and differentiation of immune cells, enhance immunity, reduce the occurrence of inflammation, and can effectively respond to the occurrence of diseases in the body. Previous studies on SAg have mainly focused on intravenous or subcutaneous injection. However, due to the targeting of direct intravenous administration and the possibility of potential adverse reactions to SAg in the preparation process of injection preparations, oral administration is a feasible strategy to reduce such adverse reactions. Although there are literature reports that oral SAg may have the effect of inhibiting tumor development, its principle is not clear (CN1647801A). At present, there are no reports on the role of Staphylococcus aureus superantigens as oral preparations in intestinal microorganisms and intestinal barrier function to protect intestinal health. Summary of the invention

[0006] In order to fill the gap in the prior art, a technical problem to be solved by the present invention is to provide a new use of superantigen or its modified form.

[0007] The inventors have been studying superantigens (SAg) for a long time and discovered for the first time that superantigens or their modified forms can withstand body temperature and have thermal stability after oral administration, and are resistant to gastric acid and various digestive enzymes. They can regulate the structure and composition of intestinal microorganisms, promote the production of short-chain fatty acids, and enhance the intestinal barrier, thereby improving intestinal function and enhancing intestinal health.

[0008] Specifically, the present invention provides the following technical solutions:

[0009] The technical solution provided by the present invention is: use of a superantigen or a modified form thereof in the preparation of food or medicine for improving intestinal function, wherein the superantigen is selected from Staphylococcus aureus enterotoxin.

[0010] As known to those skilled in the art, "intestinal tract" should be understood to include the small intestine (duodenum, jejunum, ileum), large intestine (cecum, colon, rectum) and anus. Existing medical findings show that intestinal function generally includes the following aspects:

[0011] 1. Digestion and absorption function: The intestine is the main digestive organ of the human body, responsible for the digestion of food and the absorption of nutrients. The small intestine is the main place for nutrient absorption, where food is broken down into glucose, amino acids, fatty acids, etc., and then absorbed.

[0012] 2. Excretion function: The large intestine is mainly responsible for absorbing excess water, forming feces, and excreting it out of the body.

[0013] 3. Immune function: The intestine is one of the largest immune organs in the human body. There are a large number of immune cells distributed in the intestinal mucosa, which play an important role in resisting bacteria and viruses and maintaining the stability of the intestinal environment.

[0014] 4. Function of microbial communities: There is a symbiotic relationship between the intestinal microbiota and the host, and it participates in various physiological processes such as food digestion, energy metabolism, and immune regulation.

[0015] 5. Barrier function: The intestinal barrier prevents harmful substances and pathogens from entering the blood circulation.

[0016] 6. Neuroregulatory function: The intestines have their own nervous system, known as the "intestinal brain," which is involved in regulating digestive activities and affecting emotions.

[0017] 7. Hormone secretion function: The intestines can secrete some hormones, which participate in regulating physiological functions such as blood sugar levels.

[0018] 8. Related to bone health: Substances such as short-chain fatty acids produced by intestinal flora through metabolism have a significant impact on bone growth and development.

[0019] 9. Related to the brain-gut axis: Compounds produced by intestinal flora can affect brain function by stimulating immune cells to release cytokines, leading to changes in mood and behavior.

[0020] The above intestinal functions are closely related to intestinal health or disease. Intestinal health usually refers to the absence of gastrointestinal symptoms (such as abdominal pain, diarrhea) and diseases (such as inflammatory bowel disease, colon cancer) in the intestine, as well as the absence of other local abnormalities, such as increased intestinal permeability, mucosal inflammation, or deficiency or excess of short-chain fatty acids (Heidi M Staudacher, Amy Loughman, Gut health: definitions and determinants, The Lancet Gastroenterology & Hepatology, Volume 6, Issue 4, 2021, Page 269, ISSN 2468-1253, https: / / doi.org / 10.1016 / S2468-1253(21)00071-6.)(https: / / www.sciencedirect.com / science / article / pii / S2468125321000716).

[0021] In addition, from the above functions and increasing evidence, it can be seen that intestinal function or health is closely related to the function or health of non-intestinal tissues and organs such as lungs, bones, brain and even the whole body such as nerves, endocrine and immunity. Therefore, improving intestinal function also means improving the functions of the above-mentioned related tissues, organs and body systems and thus protecting health.

[0022] According to the present invention, the improvement of intestinal function includes regulating intestinal flora, promoting the production of short-chain fatty acids and / or enhancing intestinal barrier function.

[0023] In some embodiments of the present invention, the regulating the intestinal flora is to increase the relative abundance of core bacteria or potential beneficial bacteria in the intestinal flora, and / or to decrease the relative abundance of potential harmful bacteria in the intestinal flora.

[0024] In some embodiments of the present invention, the core bacteria or potential beneficial bacteria include Lachnospiraceae_NK4A136_group, Lactobacillus and Butyricicoccus.

[0025] In some embodiments of the present invention, the potentially harmful bacteria include Ruminococcus, Shigella and Streptococcus.

[0026] In some embodiments of the present invention, the short-chain fatty acids are intestinal short-chain fatty acids; after oral administration, the superantigen or its modified form can effectively increase the content of short-chain fatty acids (acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid) in the intestine, among which acetic acid, propionic acid, butyric acid and valeric acid have a significant promoting effect.

[0027] In some embodiments of the present invention, the enhancement of intestinal barrier function is manifested in: promoting the growth and development of small intestinal mucosa and thus improving the intestinal tissue structure, stimulating the expression of mucosal proteins and tight junction proteins, and / or reducing intestinal permeability.

[0028] In some embodiments of the present invention, the promoting the growth and development of the small intestinal mucosa is promoting the growth of intestinal villi and / or increasing the small intestinal villus-gland ratio.

[0029] In some embodiments of the present invention, the mucosal protein is selected from the intestinal mucosal protein Muc-2 and the intestinal mucosal protein Muc-3, and the tight junction protein is selected from the sealing protein Claudin-1, the blocking protein Occludin-1 (also known as the closed protein Occludin-1) and the zonula occludens protein ZO-1; by upregulating the expression of these proteins, the intestinal mucosal structure is improved and the intestinal barrier function is enhanced.

[0030] In the present invention, the term "blocking protein" is equivalent to "occluden" and can also be called "occluden".

[0031] Existing technologies suggest that impaired intestinal barrier function and increased intestinal permeability are associated with a variety of diseases.

[0032] The terms "intestinal barrier" and "intestinal permeability" describe two different aspects of the same anatomical structure. The term "intestinal permeability" is mainly about allowing the exchange of solutes and fluids between the intestinal lumen and the intestinal mucosa. The term "intestinal barrier" is used to describe the complex structure that separates the internal environment from the luminal environment. The physical barrier consists of the vascular endothelium, epithelial cells and mucus layer. In addition to this physical barrier, chemical substances are also involved in the barrier function. They are composed of digestive secretions, immune molecules, cellular products such as cytokines, inflammatory mediators and antimicrobial peptides, which are mainly produced by Paneth cells in the crypts of the small intestine. The intestinal barrier basically separates the intestinal contents from the body. It consists of a single layer of cells (epithelial cells, sensory cells, and cells that produce enzymes and neurotransmitters). These cells are connected by tight junction (TJ) proteins.

[0033] In summary, there is a strong correlation between intestinal microbiota, short-chain fatty acids, intestinal mucosal barrier and intestinal function or intestinal health, which further indicates that the superantigen or its modified body can improve intestinal function or protect intestinal health, and can also be used to prevent or treat diseases and conditions related to intestinal permeability. Such diseases and conditions include intestinal inflammatory diseases and conditions, metabolic diseases and diseases affecting tissues and organs outside the intestine such as obesity, mixed connective tissue disease (MCTD), chronic inflammation including arthritis, acute inflammation including sepsis, liver diseases including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), cirrhosis and hepatocellular carcinoma, type Ⅰ diabetes, type Ⅱ diabetes, sequelae of chronic alcoholism, infections including respiratory tract infections, neurological diseases such as autism, Alzheimer's disease and Parkinson's disease, etc.

[0034] The superantigens of the present invention or their modified forms are also suitable for methods of promoting mucosal regeneration to restore the physiological structure and function of the damaged or dysfunctional mucosa caused by a disease or condition. Mucosal regeneration and tight junctions are responsible for a better barrier to molecular transport in the intestine and thus reduce inflammation of the underlying tissue. This has an impact on the treatment of diseases and conditions such as those associated with intestinal permeability and / or inflammation or dysbiosis as described above.

[0035] According to the present invention, the Staphylococcus aureus enterotoxin is selected from at least one of Staphylococcus aureus enterotoxin A (SEA), Staphylococcus aureus enterotoxin B (SEB), Staphylococcus aureus enterotoxin C (SEC), Staphylococcus aureus enterotoxin E (SEE) and Staphylococcus aureus enterotoxin G (SEG).

[0036] The Staphylococcus aureus enterotoxin C (SEC) includes Staphylococcus aureus enterotoxin C1 (SEC1), Staphylococcus aureus enterotoxin C2 (SEC2) and Staphylococcus aureus enterotoxin C3 (SEC3).

[0037] In some embodiments of the present invention, the SEA, SEB, SEC1, SEC2, SEC3, SEE, and SEG are all wild types, and their amino acid sequence NCBI numbers are: ABP87596.1, AAA88550.1, CAA29260.1, AAR20496.1, CAA35972.1, AAA26617.1, and AAC26660.1, respectively.

[0038] According to the present invention, the modified body is generally a mutant of the wild-type sequence. In some embodiments of the present invention, the modified body is selected from SEC2 modified bodies such as SEC2a, SEC2b, SEC2c previously disclosed by the applicant. The identity of the modified body to the amino acid sequence of Staphylococcus aureus enterotoxin C2 (wild type) is more than 85%, 86.61%, 97.91% or 97% respectively. In some embodiments of the present invention, the modified body comprises an amino acid sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

[0039] The oral preparation provided by the present invention contains superantigens or modified forms thereof, which are single metabolite proteins obtained by culturing, crushing and purifying genetically engineered bacteria carrying several superantigen cloned genes.

[0040] The term "cloned gene" used in the present invention refers to an in vitro recombinant gene obtained by reassembling DNA molecules derived from Staphylococcus aureus through enzyme digestion, ligation and other operations using enzymatic methods.

[0041] The term "genetically engineered bacteria" used in the present invention refers to a strain capable of effectively expressing the cloned gene obtained by transferring the above cloned gene into Escherichia coli BL21 (DE3).

[0042] The term "protein expression" used in the present invention refers to the process in which the cloned gene is transferred into Escherichia coli BL21 (DE3), and then the gene coding information is transcribed and translated by Escherichia coli BL21 (DE3) to finally form a protein.

[0043] The reason for using the prokaryotic expression system to obtain the target protein is that it can obtain large amounts of low-cost, high-purity target proteins while avoiding the biosafety risks of pathogenic hosts.

[0044] According to the present invention, the superantigen or its modified form is preferably an enteral preparation, such as commonly used oral preparations including solutions, emulsions, powders, capsules, tablets, pills, granules and granules.

[0045] In some embodiments of the present invention, the food further comprises a food additive, such as a substance that can be used to adjust the taste of the food of the present invention, and a substance that can stabilize the effective component. The substance that can adjust the taste of the oral preparation of the present invention can be a substance commonly used in foods to adjust the taste of foods, and the substance that can stabilize the effective component can be a substance commonly used in foods to extend the shelf life of foods.

[0046] In some embodiments of the present invention, the drug further includes a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable excipient.

[0047] In some embodiments of the present invention, the superantigen or its modified form is administered continuously orally.

[0048] In some embodiments of the present invention, the superantigen or its modified form is used as the sole active ingredient of the formulation.

[0049] In some embodiments of the present invention, the preparations include solutions, emulsions, powders, capsules, tablets, pills, granules and granules.

[0050] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0051] The reagents and raw materials used in the present invention are commercially available.

[0052] The positive and progressive effects of the present invention are:

[0053] The present invention utilizes superantigens or their modified forms to adopt oral preparations, which are resistant to body temperature and acid / enzyme; after administration, short-chain fatty acids in the intestine are effectively increased; the structural composition of intestinal microorganisms is changed, the upregulation of beneficial bacteria is promoted, and the enrichment of potentially harmful bacteria is inhibited; the expression of intestinal mucosal proteins and tight junction proteins can be upregulated, the pathological structure of the small intestine can be improved, the length of the villi in the small intestine can be increased, and the villus-gland ratio can be increased, which significantly improves the intestinal barrier function, can improve intestinal health, protect it from intestinal diseases, and / or enhance the ability to recover from intestinal diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 The weight change of mice during the oral toxicity experiment of detecting different superantigens or modified forms in Example 4 of the present invention.

[0055] Figure 2 This is a HE staining image of a pathological section of the small intestine of mice after oral administration of superantigen SEC2 in Example 5 of the present invention.

[0056] Figure 3 The changes in the ratio of villi to villus glands in the small intestine of mice after oral administration of different superantigens or modified forms in Example 5 of the present invention were detected (*p<0.05; **p<0.01; ***p<0.001).

[0057] Figure 4These are the results of detecting the changes in the abundance of potential beneficial bacteria and potential pathogenic bacteria in mouse feces obtained by 16s rRNA high-throughput sequencing after oral administration of different superantigens or modified forms in Example 6 of the present invention, wherein: AC are the relative abundance changes of Lachnospiraceae_NK4A136_group, Lactobacillus, and Butyricicoccus, respectively; DF are the relative abundance changes of Ruminococcus, Escherichia-Shigella, and Streptococcus, respectively (*p<0.05; **p<0.01; ***p<0.001).

[0058] Figure 5 The changes in the content of short-chain fatty acids in mouse feces after oral administration of different superantigens or modified forms in Example 7 of the present invention were detected (*p<0.05; **p<0.01; ***p<0.001).

[0059] Figure 6 The relative changes in the transcription levels of mucosal proteins in the intestine of mice measured by RT-qPCR technology after oral administration of different superantigens or modified forms in Example 8 of the present invention (*p<0.05; **p<0.01; ***p<0.001).

[0060] Figure 7 The relative changes in the transcription levels of tight junction proteins in the intestine of mice measured by RT-qPCR technology after oral administration of different superantigens or modified forms in Example 8 of the present invention (*p<0.05; **p<0.01; ***p<0.001).

[0061] Figure 8 This is the change in intestinal permeability of mice detected by FITC-dextran after oral administration of different superantigens or modified forms in Example 8 of the present invention (*p<0.05; **p<0.01; ***p<0.001). DETAILED DESCRIPTION

[0062] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0063] The culture medium used in the examples is:

[0064] Liquid LB medium: tryptone 10 g / L, yeast extract powder 5 g / L, NaCl 10 g / L; sterilize at 121°C for 20 min.

[0065] Solid LB medium: tryptone 10 g / L, yeast extract powder 5 g / L, NaCl 10 g / L, agar powder 15 g / L; sterilize at 121°C for 20 min.

[0066] Experimental animals: Female SPF BALB / c mice (6-8 weeks old, weighing 20±4 g) were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0067] Data processing method in the embodiment:

[0068] The experimental data are expressed as (mean ± SD). All data were normalized before statistical analysis, and the relative changes of the normalized data were compared. SPSS22.0 software was used for Student's t test statistical difference analysis, and p < 0.05 indicated that the difference was statistically significant.

[0069] Example 1: Construction of strains expressing typical superantigens or their modified forms

[0070] The amino acid sequences and gene coding sequences of superantigens SEC2, SEA, SEB, SEC1, SEC3, SEE, and SEG were retrieved from the NCBI database, and modified superantigens were obtained by truncation mutation or point mutation. The amino acid sequences and gene coding sequences of the above superantigens or their modified superantigens are as follows:

[0071] SEC2 (wild type, published, its amino acid sequence and nucleotide sequence are SEQ ID NOs: 1 and 2 in CN112063587A)

[0072] The NCBI publication number for the amino acid sequence of the protein is AAR20496.1; the NCBI number for the nucleotide sequence is AY450554.1

[0073] SEC2a (SEC2 truncated mutation, 86.61% identical to the wild type, has been published, its amino acid sequence and nucleotide sequence are SEQ ID NO: 3 and 4 in CN112063587A):

[0074] The amino acid sequence of the protein: SEQ ID NO: 1; wherein the amino acid sequence of the protein is as follows (the underlined part is the amino acid truncated based on the amino acid sequence of the wild-type protein):

[0075] 1 PDPTPDE LHKSSEFTGT MGNMKYLYDD HYVSATKVMS VDKFLAHDLI YNISDKKLKN

[0076] 61 YDKVKTELLN EDLAKKYKDE VVDVYGSNYY VNAYFSSKDN VGKVTGGKTAMYGGITKHEG

[0077] 121 NHFDNGNLQN VLIRVYENKR NTISFEVQTD KKSVTAQELD IKARNFLINK KNLYEFNSSP

[0078] 181 YETGYIKFIE NNGNTFWYDM MPAPGDKFDQ

[0079] SEC2b (SEC2 point mutations, T20S, D55L, T142M, TV222-223IS, 97.91% identical to the wild type, has been published, its amino acid sequence and nucleotide sequence are SEQ ID NOs: 5 and 6 in CN112063587A)

[0080] The amino acid sequence of the protein: SEQ ID NO: 2; wherein the amino acid sequence of the protein is as follows (the underlined part is the amino acid mutated based on the amino acid sequence of the wild-type protein, the same below):

[0081] 1 ESQPDPTPDE LHKSSEFTG S MGNMKYLYDD HYVSATKVMS VDKFLAHDLI YNIS L KKLK

[0082] 61 YDKVKTELLN EDLAKKYKDE VVDVYGSNYY VNAYFSSKDN VGKVTGGKTA MYGGITKHEG

[0083] 121 NHFDNGNLQN VLIRVYENKR N M ISFEVQTD KKSVTAQELD IKARNFLINK KNLYEFNSSP

[0084] 181 YETGYIKFIE NNGNTFWYDM MPAPGDKFDQ SKYLMMYNDN K IS DSKSVKI EVHLTTKNG

[0085] SEC2c (SEC2 point mutations, T20L, G22E, H118A, H122A, GKVTG102-106WWH, 97% identical to wild type, Fu X, Xu M, Song Y, et al. Enhanced interaction between SEC2 mutant and TCR Vβ induces MHC II-independent activation of T cells via PKCθ / NF-κB and IL-2R / STAT5 signaling pathways. J Biol Chem. 2018; 293(51): 19771-19784. doi: 10.1074 / jbc.RA118.003668)

[0086] The amino acid sequence of the protein: SEQ ID NO: 3; wherein the amino acid sequence of the protein is as follows:

[0087] 1ESQPDPTPDE LHKSSEFTG L M E NMKYLYDD HYVSATKVMS VDKFLAHDLI YNISDKKLKN

[0088] 61YDKVKTELLN EDLAKKYKDE VVDVYGSNYY VNAYFSSKDN V WWH GKTAMY GGITK A EGN A

[0089] 121FDNGNLQNVL IRVYENKRNT ISFEVQTDKK SVTAQELDIK ARNFLINKKN LYEFNSSPYE

[0090] 181TGYIKFIENN GNTFWYDMMP APGDKFDQSK YLMMYNDNKT VDSKSVKIEV HLTTKNG

[0091] SEA (wild type)

[0092] The NCBI publication number corresponding to the amino acid sequence of the protein is ABP87596.1, and the nucleotide sequence NCBI number is EF520720.1;

[0093] SEB (wild type, published, its amino acid sequence and nucleotide sequence are SEQ ID NO: 7 and 8 in CN112063587A)

[0094] The amino acid sequence of the protein corresponds to the NCBI publication number AAA88550.1, and the nucleotide sequence NCBI number: M11118.1;

[0095] SEC1 (wild type)

[0096] The NCBI publication number for the amino acid sequence of the protein is CAA29260.1, and the NCBI number for the nucleotide sequence is X05815.1

[0097] SEC3 (wild type)

[0098] The NCBI publication number for the amino acid sequence of the protein is CAA35972.1, and the NCBI number for the nucleotide sequence is X51661.1

[0099] SEE (wild type, published, its amino acid sequence and nucleotide sequence are SEQ ID NO: 15 and 16 in CN112063587A)

[0100] The NCBI publication number for the amino acid sequence of the protein is AAA26617.1, and the NCBI number for the nucleotide sequence is M21319.1

[0101] SEG (wild type)

[0102] The NCBI publication number corresponding to the amino acid sequence of the protein is AAC26660.1, and the nucleotide sequence NCBI number is AF064773.1.

[0103] Example 2: Preparation of several superantigens or their modified forms

[0104] In Example 1, except for the SEC2 (wild type) superantigen expression host strain which was preserved in the laboratory, the remaining superantigens and their truncated mutations and point mutations of superantigen variant gene coding sequences were handed over to BGI Genomics Co., Ltd. for whole gene synthesis.

[0105] The construction of several superantigen and modified host strains expressing them can refer to the prior art (e.g. Xu Mingkai, Zhang Chenggang, Zhou Yafeng, Zhang Xianen. 2005. Gene cloning, expression, and biological activity of Staphylococcus aureus enterotoxin C2. Progress in Biochemistry and Biophysics (SCI). 32(3): 275-281), including restriction enzyme digestion, vector ligation, expression strain transformation, positive screening, sequencing and other processes, to construct superantigen SEC2a, SEC2b, SEC2c, SEA, SEB, SEC1, SEC3, SEE, SEG expression strains. The constructed superantigen expression strains were frozen in a liquid nitrogen tank through glycerol tubes for use.

[0106] The specific preparation method of superantigen or its modified form is as follows:

[0107] 1. Cultivation and Ultrasonic Disruption of Bacteria

[0108] The frozen SEC2 genetically engineered strain was taken out from the -80°C refrigerator and quickly thawed at 37°C, and streaked into LB solid culture medium (containing kanamycin with a final concentration of 60 μg / mL) under sterile operation conditions, and cultured at 37°C for 12-18 hours; some colonies with good growth in the culture medium were picked and inoculated into LB liquid culture medium containing kanamycin, and cultured at 37°C with shaking for 12 hours to rejuvenate the strain; the above process from solid culture medium to liquid culture medium was repeated 2-3 times to obtain a strain with good growth status.

[0109] Transfer to the next level according to the inoculum volume of 1%, and culture at 37℃ with shaking until the bacterial solution OD 600 About 0.8 hours later, IPTG with a final concentration of 1 mM was added to the bacterial solution, the culture temperature was lowered to 30°C, and the shaking culture was continued for 4 hours to induce the expression of the S. aureus superantigen SEC2 exogenous protein.

[0110] After the culture was completed, the cells were collected by centrifugation at 4000 r / min for 20 minutes.

[0111] The bacterial pellet was resuspended in a 10 mM imidazole equilibration buffer, and the bacterial suspension was ultrasonically disrupted in an ice-water bath until the liquid was clear (7 s ultrasonic disruption, 7 s rest, 70 cycles, repeated three times).

[0112] 0.2% (w / v) streptomycin sulfate was added to the broken product, and the mixture was centrifuged at 4°C and 10,000 r / min for 40 minutes. The supernatant was collected and passed through a 0.45 μm filter.

[0113] 2. Purification of Staphylococcus aureus superantigen SEC2

[0114] After the bacteria obtained in the previous step are broken, the supernatant product after centrifugation is loaded onto the AKTA Ni affinity chromatography column protein purification workstation, and the target protein is purified by affinity chromatography. The specific operation is as follows:

[0115] (1) Packing a Ni affinity chromatography column according to conventional methods;

[0116] (2) 100 mM Ni ion eluent (EDTA) to remove Ni ions, 10 column volumes;

[0117] (3) Wash the column with deionized water for 10 column volumes;

[0118] (4) 500 mM NaOH wash, 10 column volumes;

[0119] (5) Wash the chromatography column with deionized water, 10 column volumes;

[0120] (6) 100 mM column regeneration solution (NiSO4) to supplement Ni ions, 10 column volumes;

[0121] (7) Rinse with deionized water, 10 column volumes;

[0122] (8) Equilibrate the column with 10 mM imidazole equilibration buffer for 10 column volumes until the UV detection value is stable;

[0123] (9) Loading protein sample onto AKTA Ni affinity chromatography column

[0124] (10) Wash the impurities with 30 mM imidazole washing buffer until UV equilibrium;

[0125] (11) The target protein was eluted with 300 mM imidazole elution buffer, and the UV detection value was collected after it began to rise until the UV reached a peak and then stopped collecting after it dropped to a stable level;

[0126] (12) The collected target protein eluate was dialyzed in a dialysis bag to remove salts, thereby obtaining the purified Staphylococcus aureus superantigen SEC2 protein, and the protein purity was detected by SDS-PAGE.

[0127] 3. Detection of the concentration of Staphylococcus aureus superantigen SEC2 protein

[0128] The single Staphylococcus aureus superantigen SEC2 obtained in the previous step was tested for protein concentration using a BCA protein quantification kit. The protein concentration test was performed according to the instructions of the kit. The specific operation is as follows:

[0129] (1) Diluting the BSA standard: dilute the BSA standard with a diluent consistent with the Staphylococcus aureus superantigen protein sample to obtain solutions with final concentrations of 2000 μg / mL, 1000 μg / mL, 500 μg / mL, 250 μg / mL, 125 μg / mL, 25 μg / mL, and 0 μg / mL, respectively, for drawing the standard curve in subsequent experiments;

[0130] (2) Prepare BCA working solution by mixing reagent A and reagent B at a volume ratio of 50:1;

[0131] (3) Add 25 μL of each Staphylococcus aureus superantigen SEC2 sample (stock solution or dilution) and 25 μL of each diluted BSA standard into the microwells of a 96-well plate, and add 200 μL of BCA working solution to each corresponding well;

[0132] (4) Cover the lid and gently shake to mix thoroughly, then incubate at 37°C in the dark for 30 min;

[0133] (5) After cooling to room temperature, a multifunctional microplate reader was used to detect the absorbance at 562 nm, and a standard curve was drawn to calculate the concentration of the Staphylococcus aureus superantigen SEC2 protein. The obtained SEC2 protein concentration was 2635 ng / mL, and the purity reached more than 95%.

[0134] The other superantigens or their variants in Example 1 were expressed and purified in the same manner as above, and the concentration and purity were tested (Table 1). After filtration and sterilization, they were stored in a -70°C refrigerator for later use.

[0135] Table 1 Concentration and purity of different purified superantigens and their variants

[0136] name concentration purity SEC2 2635ng / μL 95% SEA 1329 ng / μL 92% SEB 560ng / μL 90% SEC1 980ng / μL 90% SEC3 1210ng / μL 85% SEE 760ng / μL 80% SEG 585ng / μL 90% SEC2a 2598ng / μL 95% SEC2b 1900ng / μL 85% SEC2c 862ng / μL 95%

[0137] Example 3: Administration of oral preparations of several superantigens or their modified forms

[0138] Experimental animals: Female SPF BALB / c mice (6-8 weeks old, weighing 20±4 g) were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0139] Dosage regimen: The mice in different treatment groups were orally administered with a specific dose of the superantigen SEC2 obtained in Example 2 (specifically, the dosage for mice was 5 mg kg) by gavage of 0.2 mL of the solution (oral preparation) prepared in Example 2 every day. -1 , 10mg·kg -1 or 20 mg kg -1 ), and the blank control group (Ctrl) was gavaged with 0.2 mL of sterile PBS solution every day. The gavage was performed at regular intervals every day for 14 days.

[0140] Similarly, according to the above method, specific doses of several other superantigens or their modified forms in Example 2 were orally administered to mice daily.

[0141] Example 4: Toxicity test of oral preparations of several superantigens or their modified forms

[0142] The mice were treated according to the administration method described in Example 3. The body weight of each group of mice was weighed and recorded before each intragastric administration. The excretion of each group of mice was observed after administration.

[0143] The results showed that the drug did not cause death or abnormal changes in mice. The body weight changes of mice given the highest dose (20 mg / kg) were as follows: Figure 1 As shown, there was no abnormality; there was no abnormality in diet and mental state; and there was no abnormality in the weighing of organs such as the heart, liver, spleen, stomach, and kidneys.

[0144] Example 5: Detection of the effects of oral preparations of several superantigens or their modified forms on the morphology and structure of intestinal tissues

[0145] In order to evaluate the effect of continuous long-term oral administration of SEC2 on the intestinal morphology of mice at the tissue level, after treatment according to the administration regimen described in Example 3, the present invention performed H&E staining of tissue sections of the intestinal tract of mice. The specific experimental steps are as follows:

[0146] (1) 24 hours after the last oral administration, the mice were anesthetized and killed. The intestinal tissues of the mice were dissected and obtained, rinsed with pre-cooled PBS, the intestinal contents were removed, and the tissues were fixed with 4% paraformaldehyde. The fixed tissues were dehydrated and then embedded in paraffin;

[0147] (2) Use a microtome to slice the tissue paraffin block, with a slice thickness of approximately 6 μm;

[0148] (3) Place the tissue sections on a clean glass slide, dry them at room temperature, and bake them in a 60°C thermostat for 2 h;

[0149] (4) Soak the sections in xylene solution for 10 min and repeat three times to complete dewaxing;

[0150] (5) Hydrate the slices with ethanol of different concentrations, including 100% ethanol × 2, 95% ethanol, 85% ethanol,

[0151] 70% ethanol, 50% ethanol—3 min, PBS×2-5 min;

[0152] (6) Stain with hematoxylin solution for 3 min and wash with sterile water for 3 min;

[0153] (7) 1% hydrochloric acid ethanol separation for 2 seconds, rinse with sterile water until blue returns;

[0154] (8) Immerse in gradient ethanol solutions: 50%, 70%, and 80% ethanol solutions for 2 min each;

[0155] (9) Stain in 0.5% eosin solution for 3 min and rinse with sterile water for 2 min;

[0156] (10) Immerse in gradient ethanol solutions: 95%, 100%, and 100% ethanol solutions for 3 min each;

[0157] (11) Immerse in xylene for 5 min, repeat twice;

[0158] (12) neutral resin adhesive sealing and fixing;

[0159] (13) H&E-stained sections of the tissue were photographed under an optical microscope, and at least three representative fields of view were selected for analysis;

[0160] (14) To analyze the morphological and structural changes, villus length, and crypt depth of the small intestine, five adjacent intestinal villi and crypts were selected in each field of view to measure and count the villus length and villus-glandular ratio (V / C).

[0161] from Figure 2 It can be seen that the epithelial cells in the small intestinal tissue sections of mice in the SEC2 continuous oral administration treatment group were intact, the small intestinal villi were intact and tightly arranged, the crypts were well developed, the submucosal layer and the basal layer were of good thickness, there were few supranuclear vacuoles, and no pathological features of villus edema or epithelial damage were observed. The results of the visual analysis are shown in Figure 2. Figure 3 As shown, compared with the control group, continuous oral administration of SEC2 significantly increased the villus length of the small intestine and improved the villus-gland ratio. There was no significant difference in the promoting effect on the villus-gland ratio at different oral doses (p<0.001).

[0162] At the same time, the effects of oral administration of several other superantigens in Example 2 on the morphological structure of intestinal tissue were tested according to the above method. The specific results are shown in Figure 3 .

[0163] The results showed that the wild-type superantigens (SEC2, SEA, SEB, SEC1, SEC3, SEE, SEG) and SEC2 variants (SEC2a, SEC2b, SEC2c) did not cause damage to the small intestinal tissue structure and pathological damage when administered orally at appropriate doses. Continuous oral administration of superantigens can stimulate the small intestinal mucosa, promote the growth and development of the small intestinal mucosa, help improve the intestinal tissue structure, promote the growth of intestinal villi, increase the intestinal villus-gland ratio, and benefit intestinal health.

[0164] Example 6: Detection of the effects of oral preparations of several superantigens or their modified forms on intestinal microbial diversity

[0165] In order to evaluate the effect of continuous long-term oral administration of SEC2 on the intestinal microorganisms of mice, the present invention performed 16S rRNA high-throughput sequencing of the microbial community in the feces of mice after treatment according to the administration regimen described in Example 3. The specific experimental steps are as follows:

[0166] Total DNA was extracted from mouse feces using the FastDNA SPIN Kit (MP Biomedicals, Mpbio, USA), and the sample genome was tested by 1% agarose gel electrophoresis at a voltage of 5 V / cm for 20 min to evaluate the integrity of the DNA and to detect the concentration, purity, and fragment size of the DNA. 16S rRNA sequencing was then performed:

[0167] 1. Obtaining DNA PCR Amplification Products

[0168] PCR Primers:

[0169] 338F(5'-3')-ACTCCTACGGGAGGCAGCAG (SEQ ID NO: 4);

[0170] 806R(5'-3')-GGACTACHVGGGTWTCTAAT (SEQ ID NO: 5).

[0171] PCR reaction system:

[0172] Table 2

[0173] 5×FastPfu Buffer 4μL 2.5mM dNTPs 2μL Forward Primer (5μM) 0.8μL Reverse Primer (5μM) 0.8μL FastPfu Polymerase 0.4μL BSA 0.2μL Template DNA 10ng <![CDATA[ddH2O]]> Make up to 20 μL

[0174] PCR amplification conditions:

[0175] Pre-denaturation at 95°C for 30 min, 1 cycle; denaturation at 95°C for 30 s, annealing at 55°C for 30 s, extension at 72°C for 45 s, 40 cycles; extension at 72°C for 10 min, cooling at 37°C for 30 s, 1 cycle; storage at 10°C, ∞.

[0176] Three PCR replicates were performed for each sample for subsequent experiments.

[0177] 2. Purification of PCR Products

[0178] Before PCR purification, three replicate PCR samples were mixed and the quality of PCR products was tested by 2% agarose gel electrophoresis. After electrophoresis, the amplified fragments were recovered as follows:

[0179] Place the electrophoresis-finished agarose gel under a UV light source, use the fluorescent signal to find the target band, cut the single target band from the agarose gel, and try to remove excess gel. Use filter paper to absorb the moisture on the surface of the gel, cut it into small pieces, put it into a clean 1.5mL sterile centrifuge tube, and weigh the gel. Add 1 times the volume of the gel to the centrifuge tube with BufferPG, and warm it in a 50℃ water bath until the gel block is completely dissolved.

[0180] Add 200 μL Buffer PS to the adsorption column that has been loaded into the collection tube, centrifuge at 12,000 r / min for 1 min, discard the waste liquid in the collection tube, transfer the solution obtained in the previous step to the adsorption column, leave it at room temperature for 2 min, centrifuge at 12,000 r / min for 1 min, and discard the waste liquid in the collection tube.

[0181] Add 450 μL Buffer PW to the adsorption column, centrifuge at 12,000 r / min for 1 min, discard the waste liquid in the collection tube, and repeat the operation once.

[0182] Place the adsorption column in a new 1.5 mL centrifuge tube, add 50 μL of Buffer EB to the middle of the adsorption membrane, leave it at room temperature for 2 minutes, centrifuge it at 12,000 r for 1 minute, collect the purified DNA solution, and store it at -20°C.

[0183] 3. Library construction and sequencing

[0184] use Rapid DNA-Seq Kit was used to construct Miseq library and sequencing was performed using Illumina's NovaSeq PE250 platform (Shanghai Meiji Biopharmaceutical Technology Co., Ltd.).

[0185] 4. Bioinformatics Analysis

[0186] The sequencing data were optimized in advance, the raw data were screened using FASTP software, the sequences were spliced ​​using FLASH software, OUT clustering was performed using UPARSE software (similarity 97%), and species were annotated using RDP classifier (threshold set to 70%). The mouse intestinal microbial sequencing data were subsequently analyzed using the cloud tool platform provided by Shanghai Major Biotechnology Co., Ltd. (https: / / login.majorbio.com / login).

[0187] Similarly, the effects of oral administration of several other superantigens and different superantigen doses on intestinal microbial diversity were tested according to the above method. The results are shown in Tables 3, 4 and Figure 4 .

[0188] As shown in Table 3, the α diversity of intestinal microorganisms in each group of mice was evaluated based on the Chao index, Simpson index, and Shannon index. The results showed that after continuous oral administration of SEC2, the richness of intestinal microbial communities in each group of mice was not significantly different from that in the control group, suggesting that SEC2 does not affect the diversity within the community in regulating intestinal microorganisms.

[0189] Table 3 Effects of different superantigens and different superantigen concentrations on intestinal microbial α diversity

[0190]

[0191]

[0192] As can be seen from Table 4, the results of non-metric multidimensional scaling analysis (NMDS) based on unweighted UniFrac distance show that (Stress, R^2, and P values ​​of β diversity analysis are obtained by comparing samples in the same group with Ctrl, and a value is obtained for each group analysis). The Stress value between the control group and the SEC2 group is 0.098, P = 0.001. Stress value < 0.2 indicates that NMDS is effective, and the β diversity of the SEC2 group shows significant differences compared with the control group, indicating that continuous oral administration of SEC2 can change the structural composition of the intestinal microbiota of mice.

[0193] Table 4 Effects of different superantigens and superantigen concentrations on intestinal microbial β diversity

[0194]

[0195]

[0196] The results of species annotation analysis showed that at the phylum level, Firmicutes and Bacteroidetes were the main phyla in all treatment groups, accounting for more than 90% of the total abundance. In order to further determine the dominant microorganisms that changed significantly after SEC2 administration, the dominant genera in each group that responded to SEC2 treatment were analyzed by LEfSe, and the OTUs corresponding to these groups were statistically analyzed to evaluate their relative changes. The results showed that after SEC2 administration, the relative abundance of intestinal core bacterial genera or potential beneficial bacterial genera, including Lachnospiraceae (Lachnospiraceae_NK4A136_group), Lactobacillus, Butyricicoccus, etc., was significantly enriched ( Figure 4 AC), while significantly reducing the relative abundance of potentially harmful bacteria Ruminococcus, Escherichia-Shigella, and Streptococcus ( Figure 4 DF). The changes in intestinal microbiota were not significantly correlated with the oral dose of SEC2.

[0197] Similarly, the effects of several other superantigens and different doses of superantigen oral preparations on intestinal microbial diversity tested by the above method are shown in Tables 3, 4 and Figure 4 The results showed that superantigens taken orally at a specific dose could change the structural composition of intestinal microorganisms, promote the upregulation of beneficial bacteria, inhibit the enrichment of potentially harmful bacteria, and improve the intestinal microbial environment.

[0198] Example 7: Detection of the effects of oral preparations of several superantigens or their modified forms on intestinal microbial metabolites SCFA

[0199] In order to evaluate the effect of continuous long-term oral administration of SEC2 on the metabolites of intestinal microorganisms in mice, after treatment according to the administration regimen described in Example 3, the present invention used gas chromatography-mass spectrometry (GC-MS) to detect short-chain fatty acids SCFA in mouse feces. The specific experimental steps are as follows:

[0200] 1. Preparation of standard curve for short-chain fatty acid detection

[0201] Six short-chain fatty acid standards to be tested (acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid) were prepared into mixed standard solutions with a final concentration of 1 mg / mL, and diluted to six concentrations of 1000 μg / mL, 500 μg / mL, 100 μg / mL, 50 μg / mL, 10 μg / mL, and 5 μg / mL in sequence; 1 μL of the standard of each concentration was taken into a clean centrifuge tube, and 150 μL of ultrapure water, 30 μL of 0.5M Na2HPO4 solution, and 100 μL of 5% (m / v) pentafluorobenzyl bromide-acetone solution were added respectively; the mixture was placed in a 60°C water bath for reaction for 40 minutes, 200 μL of n-hexane was added, and the mixture was mixed and centrifuged at 3000 g for 15 minutes; the upper n-hexane phase was taken for gas chromatography-mass spectrometry analysis and detection, and a short-chain fatty acid standard curve was drawn.

[0202] 2. Extraction of short-chain fatty acids from mouse feces

[0203] Mouse feces were placed in a clean mortar, and liquid nitrogen was added for grinding. 0.5 g of the ground feces powder was weighed and transferred to a 1.5 mL centrifuge tube. 170 μL of ultrapure water, 30 μL of 0.5 M Na2HPO4 solution, and 100 μL of 5% (m / v) pentafluorobenzyl bromide-acetone solution were added to the centrifuge tube. The mixed system was placed in a 60°C water bath for reaction for 40 minutes, 200 μL of n-hexane was added, and the mixture was mixed and centrifuged at 3000 g for 15 minutes. The upper n-hexane phase was taken for detection on the machine.

[0204] 3. Short-chain fatty acids gas chromatography-mass spectrometry detection

[0205] The derivatized samples were analyzed for short-chain fatty acids using a gas chromatograph-mass spectrometer (model ISQ7000 GC-MS) and a TR-WAX MC-GC Column (30 m, 0.25 mm ID, 0.25 μm) from Thermo Fisher Scientific. 1 μL of the sample was injected in splitless mode, and the carrier gas was high-purity helium at a flow rate of 1 mL / min. The gradient temperature program was as follows: the furnace temperature was 60 °C and maintained for 2 minutes, then increased to 100 °C at 20 °C / min, increased to 110 °C at 2 °C / min, increased to 145 °C at 10 °C / min, and increased to 240 °C at 50 °C / min. The temperatures of the injection port, ion source, and transfer line were 250 °C, 280 °C, and 280 °C, respectively. The data were collected in selected ion scanning mode (SIM).

[0206] The results of short-chain fatty acids are as follows Figure 5 As shown in the figure, compared with the control group, the SEC2 oral administration group showed significant upregulation of acetate, propionate, butyrate, isobutyrate, valerate, isovalerate and total SCFAs. The changes in acetate, propionate, butyrate and valerate were large. The changes in butyrate were positively correlated with the enrichment of Butyricicoccus.

[0207] At the same time, the effects of several other superantigens and different doses of superantigen oral preparations on short-chain fatty acids tested by the above method are shown in the specific results. Figure 5 The above results show that continuous oral administration of SEC2 will lead to positive regulation of the composition and structure of the intestinal microbiota, maintain intestinal microbial homeostasis by promoting the enrichment of beneficial bacteria, and increase the content of short-chain fatty acids. SCFA can maintain epithelial barrier function, stabilize intestinal pH, regulate immune cell responses, and inhibit intestinal inflammatory responses, thereby achieving a beneficial effect on intestinal health.

[0208] Example 8: Detection of the effects of oral preparations of several superantigens or their modified forms on the intestinal mucosal barrier

[0209] In order to evaluate the effect of continuous long-term oral administration of SEC2 on the intestinal mucosal barrier of mice, after treatment according to the dosing regimen described in Example 3.

[0210] First, the present invention uses the RT-qPCR method to detect the transcription levels of mucosal proteins Muc-2, Muc-3 and major tight junction proteins claudin-1, occludin-1 (also known as blocking protein-1), and zonula occludens-1 (ZO-1) in the intestine of mice after continuous oral administration. The specific experimental steps are as follows.

[0211] (1) Extraction of total RNA from mouse intestine:

[0212] Refer to the instructions of RNA extraction kit (RNAiso plus, Takara, JPN) and perform the following operations:

[0213] After killing the mice by cervical dislocation, the front end tissue samples of the mouse small intestine were quickly extracted, the outer adhesion fat was removed and the small intestine was cut into small pieces. 50 mg was weighed and placed in a 1.5 mL RNase-free centrifuge tube, and 1 mL RNAiso plus solution was added to fully grind into a homogenate. The mixture was allowed to stand for 5 min at room temperature, and then centrifuged at 12,000 g at 4°C for 5 min. After centrifugation, the supernatant solution was aspirated and placed in a new 1.5 mL RNase-free centrifuge tube, 1 / 5 RNAiso plus volume of chloroform was added, the mixture was shaken vigorously, and the mixture was allowed to stand for 5 min at room temperature, and then centrifuged at 12,000 g at 4°C for 15 min. After centrifugation, the supernatant solution was aspirated and placed in a new 1.5 mL RNase-free centrifuge tube, an equal volume of isopropanol was added to the supernatant solution, the mixture was shaken slightly, the mixture was allowed to stand for 10 min at room temperature, and then centrifuged at 12,000 g at 4°C for 10 min. After centrifugation, the supernatant was discarded, the bottom precipitate was retained, 1 mL of 75% ethanol was added, the precipitate was gently inverted up and down to wash, and then centrifuged at 7,500 g at 4°C for 5 min. After centrifugation, the supernatant was carefully discarded, and the precipitate was dried at room temperature to remove the ethanol. DEPC water was added to completely dissolve the precipitate, and 3-5 μL was aspirated to detect the concentration and purity of RNA using Nanodrop 2000.

[0214] (2) Reverse transcription of intestinal total RNA: refer to the reverse transcription kit (PrimeScript TM RT reagent Kit with gDNA Eraser, Takara, JPN) instructions for the following operations:

[0215] a. The reagents for removing genomic DNA are shown in Table 5:

[0216] Table 5

[0217] Reagents Dosage 5×gDNA Eraser Buffer 2.0μL gDNA Eraser 1.0μL Total RNA 20μL reaction system total RNA 500ng <![CDATA[RNase Free dH2O]]> Up to 10μL

[0218] The reaction conditions were 42°C, 2 min; and stored at 4°C.

[0219] b. Reagents for reverse transcription reaction are shown in Table 6:

[0220] Table 6

[0221]

[0222] The reaction conditions were: 37°C for 15 min; 85°C for 5 s.

[0223] (3) RT-qPCR detection of gene transcription levels

[0224] The RT-qPCR method was used to detect the transcription levels of Muc-2, Muc-3Clauin-1, Occludin-1, and ZO-1 genes obtained from the cDNA obtained by the above reverse transcription reaction.

[0225] The RT-qPCR reaction system is shown in Table 7:

[0226] Table 7

[0227] Reagents Dosage SYBR Premix Ex TaqⅡ 10μL Prime F 0.8μL Prime R 0.8μL DNA template 1.0μL <![CDATA[ddH2O]]> Up to 20μL

[0228] Amplification conditions:

[0229] Pre-denaturation at 95°C for 30 s, 1 cycle; denaturation at 95°C for 15 s, annealing at 55°C for 45 s, extension at 72°C for 45 s, 40 cycles; extension at 72°C for 5 min, cooling at 37°C for 30 s, 1 cycle.

[0230] The required primer list is shown in Table 8:

[0231] Table 8 Primer sequences for mucin and tight junction protein target genes and internal reference genes

[0232]

[0233]

[0234] (4) Data analysis:

[0235] The difference in gene expression was measured in the form of relative quantification, using the difference in Ct value between the gene to be tested and the reference gene, i.e., 2 -ΔΔCt Method to calculate.

[0236] Furthermore, the change of intestinal permeability of mice after oral administration was detected by intragastric administration of fluorescein isothiocyanate-dextran (FITC-dextran, Chondrex (USA)). The specific experimental steps are as follows:

[0237] Before the mice were anesthetized and killed, 25 mg / mL FITC-dextran was diluted with PBS to a final concentration of 2.5 mg / mL and administered intragastrically, with 50 μL administered intragastrically to each mouse. The mice were anesthetized 3 hours after FITC-dextran administration, and about 1.5 mL of blood was collected from the eyeball into an EP tube, which was allowed to stand in a 37°C incubator for 30 minutes and then treated at 4°C overnight. After standing, the blood was centrifuged at 4°C and 3000 r for 10 minutes to obtain about 200 μL of the supernatant after centrifugation. The resulting serum was graded diluted (10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5) and then perform fluorescence intensity detection on a fully automatic multifunctional microplate reader, and select samples that meet the fluorescence detection range for fluorescence intensity calculation. The excitation light wavelength is 490 nm and the emission wavelength is 520 nm.

[0238] Results from Figure 6 It can be seen that compared with the control group, after continuous oral administration of SEC2, the transcription levels of mucosal proteins Muc2 and Muc3 in the intestine of mice increased significantly (p<0.01), and with the increase of the dosage, the transcription levels of mucosal proteins Muc2 and Muc3 also continued to increase. Figure 7 The results showed that the three major tight junction proteins were significantly upregulated after continuous oral administration of SEC2. No significant differences were observed in the upregulation of Claudin-1, Occludin-1, and ZO-1 between different doses. Figure 8 As shown in the figure, after oral administration of SEC2, the fluorescence signal intensity of FITC-dextran in the blood gradually decreased, indicating that the intestinal permeability of mice showed a decreasing trend, reflecting the trend of enhanced intestinal barrier function, which became more significant with the increase of the dosage. This is similar to the trend of the detected mucosal protein Muc2 and Muc3 gene expression.

[0239] Similarly, the effects of several other superantigens and different doses of superantigen oral preparations on intestinal mucosal proteins, tight junction proteins, and intestinal permeability tested by the above method were as follows. Figure 6-8 Different superantigens exhibit the same characteristics as SEC2. Continuous oral administration of several superantigens, at appropriate doses, can effectively stimulate the expression of mucosal proteins and tight junction proteins and reduce intestinal permeability.

[0240] These results show that long-term continuous oral administration of superantigens can stimulate the small intestinal mucosa, promote the growth and development of the small intestinal mucosa, promote intestinal mucus secretion, enhance the tight junctions of intestinal epithelial cells, and regulate the proliferation and differentiation of intestinal epithelial cells. After oral administration of superantigens, under the joint action of short-chain fatty acids, mucosal proteins and tight junction proteins, the intestinal barrier function is promoted.

[0241] In the present invention, several oral agents of Staphylococcus aureus superantigens or their modified forms are provided, which can effectively protect intestinal health. Wild-type superantigens (SEC2, SEA, SEB, SEC1, SEC3, SEE, SEG) and SEC2 modified forms (SEC2a, SEC2b, SEC2c) improve the small intestinal tissue structure during 14 consecutive days of oral administration, can regulate the intestinal microbial structure and composition, promote the enrichment of beneficial bacteria and inhibit potential pathogenic bacteria, and at the same time, upregulate the production of short-chain fatty acids, which are beneficial to intestinal epithelial cells and intestinal mucosa; the significant upregulation of tight junction proteins between mucosal proteins and epithelial cells and the reduction of intestinal permeability also show the promoting effect of oral superantigens on intestinal barrier function.

[0242] The above embodiments have been described and listed in detail for the technical solutions of the present invention, and their purpose is to enable those skilled in the art to understand the content of the invention and implement it accordingly, and they cannot be used to limit the scope of protection of the present invention. Modifications to the above embodiments or equivalent alternatives without departing from the spirit of the present invention are all within the scope of protection claimed by the present invention.

Claims

1. Use of a superantigen or a modified form thereof in the preparation of food or medicine for improving intestinal function, wherein the superantigen is selected from Staphylococcus aureus enterotoxin.

2. The use according to claim 1, characterized in that The Staphylococcus aureus enterotoxin is selected from at least one of Staphylococcus aureus enterotoxin A (SEA), Staphylococcus aureus enterotoxin B (SEB), Staphylococcus aureus enterotoxin C (SEC), Staphylococcus aureus enterotoxin E (SEE) and Staphylococcus aureus enterotoxin G (SEG); Preferably, the SEC is selected from SEC1, SEC2 and SEC3; More preferably, the modified form is selected from SEC2 modified forms.

3. The use according to claim 1 or 2, characterized in that: The improvement of intestinal function includes regulating intestinal flora, promoting the production of short-chain fatty acids and / or enhancing intestinal barrier function.

4. The use according to claim 3, characterized in that The regulating of the intestinal flora is to increase the relative abundance of core bacteria or potential beneficial bacteria in the intestinal flora, and / or to decrease the relative abundance of potential harmful bacteria in the intestinal flora; Preferably, the core bacteria or potential beneficial bacteria include Lachnospiraceae_NK4A136_group, Lactobacillus, Butyricicoccus; and / or, the potential harmful bacteria include Ruminococcus, Escherichia-Shigella, Streptococcus.

5. The use according to claim 3 or 4, characterized in that: The short-chain fatty acids are intestinal short-chain fatty acids.

6. The use according to any one of claims 3 to 5, characterized in that: The enhancement of intestinal barrier function includes: promoting the growth and development of small intestinal mucosa, stimulating the expression of mucosal proteins and tight junction proteins, and / or reducing intestinal permeability; Preferably, the promotion of the growth and development of small intestinal mucosa is to promote the growth of intestinal villi and / or increase the small intestinal villus-gland ratio; and / or, the mucosal protein is selected from the intestinal mucosal protein Muc-2 and the intestinal mucosal protein Muc-3, and the tight junction protein is selected from the sealing protein Claudin-1, the blocking protein Occludin-1 and the zonula occludens protein ZO-1.

7. The use according to any one of claims 2 to 6, characterized in that: The amino acid sequences of SEA, SEB, SEC1, SEC2, SEC3, SEE and SEG are NCBI numbers: ABP87596.1, AAA88550.1, CAA29260.1, AAR20496.1, CAA35972.1, AAA26617.1 and AAC26660.1, respectively, and the modified form has at least 85% identity with the amino acid sequence of SEC2; And / or, the amino acid sequence of the modified form is shown in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:

3.

8. The use according to any one of claims 1 to 7, characterized in that: The superantigen or its modified form is a preparation for enteral administration, such as an oral preparation; The food further comprises a food additive; and / or, The drug also includes a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable excipient.

9. The use according to claim 8, characterized in that The superantigen or its modified form is used as the sole active ingredient of the preparation; and / or, The preparations include solutions, emulsions, powders, capsules, tablets, pills, granules and granules.

Citation Information

Patent Citations

  • Application of super antigen or variant thereof in preparation of CAR immune cell

    CN112063587A

  • Staphylococcus aureus metabolic product medicine oral preparation and its use

    CN1647801A